Alberto Mestre
Infectious Disease · Miami, FLNPI 1487625059
Payments from drug & device makers
Across 427 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$1K
- Johnson & Johnson$1K
- Merck$821
- EMD Serono, Inc.$420
- AbbVie$350
- plus $1K from 17 others
What the payments were for
- Food & beverage$8,02299%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 135 | $2,397 |
| Gilead | 66 | $1,433 |
| Johnson & Johnson | 79 | $1,324 |
| Merck | 40 | $821 |
| EMD Serono, Inc. | 22 | $420 |
| AbbVie(2 entities) | 21 | $350 |
| Insmed, Inc. | 11 | $242 |
| Kowa Pharmaceuticals America, Inc. | 6 | $172 |
| Amgen | 8 | $152 |
| Theratechnologies Inc. | 6 | $134 |
| Paratek Pharmaceuticals, Inc. | 7 | $132 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $86 |
| Pfizer | 5 | $82 |
| Janssen Products, LP | 1 | $70 |
| GSK | 4 | $61 |
| AstraZeneca | 3 | $57 |
| Arbor Pharmaceuticals, Inc. | 2 | $40 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $40 |
| Exact Sciences | 1 | $24 |
| Mylan Institutional Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$8,113 in reported general payments places this provider in the 75th percentile of 669 infectious disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 37 | $139,858 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $28,783 |
| AptivusTipranavir | 13 | $26,176 |
| SelzentryMaraviroc | 12 | $20,346 |
| FarxigaDapagliflozin Propanediol | 12 | $16,248 |
| Diclofenac Sodium | 17 | $671 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 16 | $284 |
| Fluticasone Propionate | 14 | $236 |
| Metformin Hcl | 20 | $228 |
| Lisinopril | 24 | $177 |
| Losartan Potassium | 21 | $172 |
| Levothyroxine Sodium | 16 | $147 |
| Rosuvastatin Calcium | 14 | $146 |
| Atorvastatin Calcium | 19 | $76 |
| Tamsulosin Hcl | 11 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,433 | $168,64150 claims |
| PfizerSelzentry | $82 | $20,34612 claims |
| AstraZenecaFarxiga | $57 | $16,24812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Miami
- Dushyantha JayaweeraMiami$5.1M
- Efrain GarciaMiami$2.5M
- Susanne LewisMiami$1.9M
- Luis Mendez MuletMiami$1M
- Hansel TookesMiami$771K
- Juan Perez MoralesMiami$561K
- Douglas BrustMiami$467K
- Hector BolivarMiami$424K
- Allan RodriguezMiami$341K
- Ricardo FrancoMiami$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.